Si norad

Manufactured by RiboBio

Sourced in China

Si-NORAD is a laboratory equipment product designed for the detection and quantification of small interfering RNA (siRNA) molecules. It functions as a tool for researchers to analyze and measure the expression levels of siRNA within biological samples.

Automatically generated - may contain errors

Lab products found in correlation

Lipofectamine 2000, by Thermo Fisher Scientific (3 mentions) Si nc, by RiboBio (2 mentions) Pcdna3.1 nc, by RiboBio (1 mentions)

2 protocols using si norad

Silencing lncRNA NORAD in CRC Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

CRC cells were transfected with three siRNAs specifically targeting lncRNA NORAD (si-NORAD [no 1, no 2, and no 3], 100 nM each; Ribobio, Guangzhou, People’s Republic of China) or negative control siRNA (si-NC; Ribobio), which was performed using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. Knockdown effect of si-NORAD was examined by RT-qPCR using RNA extracted 48 hours after transfection. The siRNA sequences of lncRNA NORAD and negative control used in this study are listed in Table S1.

Wang L., Du L., Duan W., Yan S., Xie Y, & Wang C. (2018). Overexpression of long noncoding RNA NORAD in colorectal cancer associates with tumor progression. OncoTargets and therapy, 11, 6757-6766.

+ Open protocol

+ Expand

Overexpression and Knockdown of Key Regulators

Check if the same lab product or an alternative is used in the 5 most similar protocols

miR-28-3p-inhibitor, small interfere (si) RNA targeting NORAD (si-NORAD), plasmid overexpressing E2F2 (pcDNA3.1-E2F2), and the corresponding controls (miR-28-3p-negative control (NC), si-NC, and pcDNA3.1-NC) (all from RiboBio Co., Ltd, Guangzhou, Guangdong China) were transfected into cells by Lipofectamine 2000 (Invitrogen Inc., Carlsbad, CA, USA) following the manufacturers’ instructions. After 48 h of transfection, all cells were preserved for further analysis.

Mao W., Wang S., Chen R., He Y., Lu R, & Zheng M. (2022). lncRNA NORAD promotes lung cancer progression by competitively binding to miR-28-3p with E2F2. Open Medicine, 17(1), 1538-1549.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!